The Oncology Institute, Inc. (TOI)
| Market Cap | 112.84M |
| Revenue (ttm) | 309.88M |
| Net Income (ttm) | -75.41M |
| Shares Out | 73.75M |
| EPS (ttm) | -0.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 434,806 |
| Open | 1.75 |
| Previous Close | 1.71 |
| Day's Range | 1.47 - 1.76 |
| 52-Week Range | 0.33 - 2.66 |
| Beta | 0.84 |
| Analysts | Strong Buy |
| Price Target | 2.00 (+30.72%) |
| Earnings Date | Nov 8, 2023 |
About TOI
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates in three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient blood product transfusions, and patient support services. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for TOI stock is "Strong Buy" and the 12-month stock price forecast is $2.0.
News
The Oncology Institute Announces Third Quarter 2023 Earnings Release Date and Conference Call
CERRITOS, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that the com...
The Oncology Institute Names Jeremy Castle as Chief Operations Officer
CERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, ...
The Oncology Institute Executive Leaders to Present at the 2023 Association for Value-Based Cancer Care (AVBCC) Summit
CERRITOS, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (TOI) is excited to announce that multiple executives including CEO, Dr. Daniel Virnich, CMO, Dr. Yal...
The Oncology Institute Regains Compliance with Nasdaq Listing Requirements
CERRITOS, California, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI) (the “Company”), one of the largest value-based community oncology groups in the United States, today anno...
Ambience Healthcare and The Oncology Institute (TOI) Partner to Create a Best-in-Class Oncology Experience for Patients and Clinicians, Leveraging Breakthrough Generative AI Technology
CERRITOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Ambience Healthcare, a market leader in generative AI technology for clinical documentation, workflows, and patient experience, and The Oncology Ins...
The Oncology Institute Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance
CERRITOS, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, ...
The Oncology Institute Announces Second Quarter 2023 Earnings Release Date and Conference Call
CERRITOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the comp...
The Oncology Institute Announces Leadership Transition
Dr. Daniel Virnich promoted from President to CEO. Brad Hively will transition from CEO to Vice Chairman. Dr. Daniel Virnich promoted from President to CEO. Brad Hively will transition from CEO to Vic...
The Oncology Institute (TOI) and Massive Bio Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research
CERRITOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), has announced a non-exclusive partnership with Massive Bio, a leader in leveraging artificial intelligence and...
The Oncology Institute to Open Project Southland
TOI acquires SRON and expands radiation oncology services in the Greater LA area TOI acquires SRON and expands radiation oncology services in the Greater LA area
Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research
NEW YORK--(BUSINESS WIRE)--Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The O...
The Oncology Institute Featured on Four Abstracts at ASCO 2023 Annual Meeting
CERRITOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, is featured on four authored abs...
The Oncology Institute to Participate at Upcoming Investor Conferences
CERRITOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that senior manageme...
The Oncology Institute Reports First Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance
CERRITOS, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, t...
The Oncology Institute Announces a Strategic Partnership with IDEOlogy Health to Provide Customized Medical Education
CERRITOS, Calif. and AUSTIN, Texas , May 4, 2023 /PRNewswire/ -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, announced to...
The Oncology Institute Announces First Quarter 2023 Earnings Release Date and Conference Call
CERRITOS, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the com...
CORRECTION -- The Oncology Institute Reports Updated Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023
CERRITOS, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- The Company recorded adjustments to its “goodwill impairment charges” and “income tax benefit” line items on the “Consolidated Statements of Operat...
The Oncology Institute Reports Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023
CERRITOS, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States,...
The Oncology Institute Announces Fourth Quarter & Full Year 2022 Earnings Release Date and Conference Call
CERRITOS, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the comp...
The Oncology Institute Expands Into Chino, CA
CERRITOS, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, has acquired the Chino, C...
The Oncology Institute Expands into Miami-Dade County, Hires National Oncology Leader Dr. Roberto Ochoa
TOI continues expansion in South Florida TOI continues expansion in South Florida
The Oncology Institute Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Guidance
CERRITOS, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, today reported financial ...
The Oncology Institute to Participate at the Credit Suisse 31st Annual Healthcare Conference
CERRITOS, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that its Chief Exec...
The Oncology Institute Executives to Speak at Key Industry Conferences in Q4
Publicly traded company leaders will share perspectives on the future of value-based oncology care Publicly traded company leaders will share perspectives on the future of value-based oncology care
The Oncology Institute Enrolls Nation's First Two Patients in a Phase 3 Open-Label, Randomized Clinical Trial of Pirtobrutinib
Value-based Oncology Leader Improving Access to Cutting-Edge Therapies Value-based Oncology Leader Improving Access to Cutting-Edge Therapies